2022 News Release

Three Pharmaceutical Organizations of Japan, the U.S. and Europe: Joint Statement on the Fiscal 2023 NHI Drug Price Revision

The 16th Annual Survey on Sei-katsu-sha Attitudes Toward Drugs and the Pharmaceutical Industry

Three Pharmaceutical Organizations of the U.S., Europe and Japan: Joint Position on the Midyear NHI Price Revision

Following the Cabinet Decision on the Second Supplementary Budget for FY2022

JPMA Code of Practice "Code Understanding Promotion Month

Greater Tokyo Biocommunity (GTB): Collaboration among the University of Tokyo, the Medical and Dental University, and JPMA at Hongo, Ochanomizu, and Tokyo Station Area

Election of New Board Members

JPMA Chairman's Press Conference held on August 30

Toward the Creation of an Ecosystem to Enhance Japan's Drug Discovery Capabilities

TRIPS Weber Agreement at the 12th WTO Ministerial Conference

Joint production and release by the Council for the Proper Use of Drugs and Japan Pharmaceutical Manufacturers Association
Educational Video on Polypharmacy "How Many of Your Drugs Are You Taking?

Statement by the R&D-Based Pharmaceutical Industry on the Consultation on the Exemption from Intellectual Property Protection Obligations Scheduled for the 12th WTO Ministerial Conference

Proposal by the Three Pharmaceutical Associations of Japan, the U.S., and Europe: Joint Proposal for the Formulation of a "Framework Policy" and a "Growth Strategy

Discussion on the Exemption of Intellectual Property from the Obligation to Protect at the WTO

11th Asian Pharmaceutical Association Conference (APAC) Press Conference on April 6, 2011

Following the 11th APAC Conference

Three organizations involved in clinical trials and clinical studies jointly formulated the "Data Integrity Declaration

Joint Statement on "Three Priorities to Increase Access to COVID-19 Vaccine Immediately

JPMA's Communication Plan for FY2021

JPMA has set up an official Twitter account.

JPMA Chairman's Press Conference held on January 20

JPMA Chairman's New Year Message for 2022